$ACT News Pfizer sales fall less than expected
Post# of 144509
Posted On: 10/28/2014 11:15:51 AM
$ACT News
Pfizer sales fall less than expected 7:34 a.m. Today - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Small-cap buckling and trap doors could make for a brutal earnings season 6:07 a.m. Oct. 8, 2014 - Shawn Langlois
Valeant to boost Allergan bid by $15 a share: report 5:49 p.m. Oct. 7, 2014 - Russ Britt
Actavis agrees to acquire Durata Therapeutics 8:44 a.m. Oct. 6, 2014 - Tess Stynes
Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
In focus: Finally, a breakdown 7:41 p.m. Oct. 1, 2014 - Lawrence G. McMillan
In focus: Back in the trading range 2:27 p.m. Sept. 24, 2014 - Lawrence G. McMillan
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff
In focus: Market giving mixed signals 7:03 p.m. Sept. 17, 2014 - Lawrence G. McMillan
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang
3 Generics Stocks to Buy Now - Analyst Blog 47 min ago - Zacks.com
Pfizer Sales Drop Less Than Expected 7:36 a.m. Today - The Wall Street Journal Interactive Edition
Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog 5:40 p.m. Oct. 27, 2014 - Zacks.com
Lannett Co. Gets Growth Rx In Generic Drugs Group 4:59 p.m. Oct. 27, 2014 - Investors Business Daily
Will Growth Measures Reflect on Aetna (AET) Q3 Earnings? - Analyst Blog 2:21 p.m. Oct. 27, 2014 - Zacks.com
3 Drugs Stocks Dragging The Industry Down 1:20 p.m. Oct. 27, 2014 - TheStreet.com
The Medicines Co.'s Q3 Earnings Fall Y/Y, Guidance Lowered - Analyst Blog 1:00 p.m. Oct. 27, 2014 - Zacks.com
Allergan Lifts Guidance; Valeant Suggests Higher Bid 11:17 a.m. Oct. 27, 2014 - Investors Business Daily
Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? - Analyst Blog 4:11 p.m. Oct. 24, 2014 - Zacks.com
Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog 3:48 p.m. Oct. 24, 2014 - Zacks.com
Stock Charts Show Stocks' Health, Optimal Buy Point 4:54 p.m. Oct. 23, 2014 - Investors Business Daily
Illumina Breaks Out Of Double-Bottom Base 4:53 p.m. Oct. 22, 2014 - Investors Business Daily
3 Irish Specialty Pharmaceutical Stocks to Buy After Tax Inversion Implosion 9:13 a.m. Oct. 22, 2014 - 247WallSt.com
Akorn (AKRX) Looks Good: Stock Adds 5.8% in Session - Tale of the Tape 9:04 a.m. Oct. 22, 2014 - Zacks.com
Synergy Pharma presents plecanatide IBS-C clinical trial results 10:11 a.m. Oct. 21, 2014 - Seeking Alpha
Digging Deeper Into Valeant's Organic Growth Claims 7:14 a.m. Oct. 21, 2014 - Seeking Alpha
PEG Ratio vs. the P/E Ratio - Screen of the Week 4:14 a.m. Oct. 21, 2014 - Zacks.com
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings 5:01 p.m. Oct. 20, 2014 - Investors Business Daily
Akorn Finds Institutional Support In Base 5:36 p.m. Oct. 17, 2014 - Investors Business Daily
Ironwood/Actavis Move Linzess into Phase II Study for OIC - Analyst Blog 4:40 p.m. Oct. 17, 2014 - Zacks.com
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
Actavis Confirms Generic Quillivant XR® Patent Challenge 8:00 a.m. Oct. 16, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting 8:00 a.m. Oct. 9, 2014 - BusinessWire - BZX
EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc – DRTX 11:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 11:34 a.m. Oct. 6, 2014 - PR Newswire - PRF
Actavis to Acquire Durata Therapeutics, Inc. 8:00 a.m. Oct. 6, 2014 - PR Newswire - PRF
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents 7:30 a.m. Oct. 2, 2014 - GlobeNewswire
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Butrans® Patent Challenge 4:05 p.m. Sept. 25, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 10:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 9:39 a.m. Sept. 24, 2014 - PR Newswire - PRF
Twenty Employers to Attend Annual Life Science Hiring Event Next Week 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension 5:10 p.m. Sept. 9, 2014 - PR Newswire - PRF
Pfizer sales fall less than expected 7:34 a.m. Today - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Small-cap buckling and trap doors could make for a brutal earnings season 6:07 a.m. Oct. 8, 2014 - Shawn Langlois
Valeant to boost Allergan bid by $15 a share: report 5:49 p.m. Oct. 7, 2014 - Russ Britt
Actavis agrees to acquire Durata Therapeutics 8:44 a.m. Oct. 6, 2014 - Tess Stynes
Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
In focus: Finally, a breakdown 7:41 p.m. Oct. 1, 2014 - Lawrence G. McMillan
In focus: Back in the trading range 2:27 p.m. Sept. 24, 2014 - Lawrence G. McMillan
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff
In focus: Market giving mixed signals 7:03 p.m. Sept. 17, 2014 - Lawrence G. McMillan
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang
3 Generics Stocks to Buy Now - Analyst Blog 47 min ago - Zacks.com
Pfizer Sales Drop Less Than Expected 7:36 a.m. Today - The Wall Street Journal Interactive Edition
Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog 5:40 p.m. Oct. 27, 2014 - Zacks.com
Lannett Co. Gets Growth Rx In Generic Drugs Group 4:59 p.m. Oct. 27, 2014 - Investors Business Daily
Will Growth Measures Reflect on Aetna (AET) Q3 Earnings? - Analyst Blog 2:21 p.m. Oct. 27, 2014 - Zacks.com
3 Drugs Stocks Dragging The Industry Down 1:20 p.m. Oct. 27, 2014 - TheStreet.com
The Medicines Co.'s Q3 Earnings Fall Y/Y, Guidance Lowered - Analyst Blog 1:00 p.m. Oct. 27, 2014 - Zacks.com
Allergan Lifts Guidance; Valeant Suggests Higher Bid 11:17 a.m. Oct. 27, 2014 - Investors Business Daily
Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? - Analyst Blog 4:11 p.m. Oct. 24, 2014 - Zacks.com
Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog 3:48 p.m. Oct. 24, 2014 - Zacks.com
Stock Charts Show Stocks' Health, Optimal Buy Point 4:54 p.m. Oct. 23, 2014 - Investors Business Daily
Illumina Breaks Out Of Double-Bottom Base 4:53 p.m. Oct. 22, 2014 - Investors Business Daily
3 Irish Specialty Pharmaceutical Stocks to Buy After Tax Inversion Implosion 9:13 a.m. Oct. 22, 2014 - 247WallSt.com
Akorn (AKRX) Looks Good: Stock Adds 5.8% in Session - Tale of the Tape 9:04 a.m. Oct. 22, 2014 - Zacks.com
Synergy Pharma presents plecanatide IBS-C clinical trial results 10:11 a.m. Oct. 21, 2014 - Seeking Alpha
Digging Deeper Into Valeant's Organic Growth Claims 7:14 a.m. Oct. 21, 2014 - Seeking Alpha
PEG Ratio vs. the P/E Ratio - Screen of the Week 4:14 a.m. Oct. 21, 2014 - Zacks.com
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings 5:01 p.m. Oct. 20, 2014 - Investors Business Daily
Akorn Finds Institutional Support In Base 5:36 p.m. Oct. 17, 2014 - Investors Business Daily
Ironwood/Actavis Move Linzess into Phase II Study for OIC - Analyst Blog 4:40 p.m. Oct. 17, 2014 - Zacks.com
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
Actavis Confirms Generic Quillivant XR® Patent Challenge 8:00 a.m. Oct. 16, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting 8:00 a.m. Oct. 9, 2014 - BusinessWire - BZX
EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc – DRTX 11:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 11:34 a.m. Oct. 6, 2014 - PR Newswire - PRF
Actavis to Acquire Durata Therapeutics, Inc. 8:00 a.m. Oct. 6, 2014 - PR Newswire - PRF
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents 7:30 a.m. Oct. 2, 2014 - GlobeNewswire
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Butrans® Patent Challenge 4:05 p.m. Sept. 25, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 10:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 9:39 a.m. Sept. 24, 2014 - PR Newswire - PRF
Twenty Employers to Attend Annual Life Science Hiring Event Next Week 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension 5:10 p.m. Sept. 9, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼